RUTHERFORD, N.J., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGIX" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, was featured in an article in USA TODAY titled "Targeted therapy and companion diagnostics go hand and hand." The article is available online at:
Additionally, the September 20 print edition of USA TODAY features a panel discussion with Dr. Raju Chaganti, founder and chairman of CGIX. In the panel discussion, Dr. Chaganti and other leading oncology experts share insights about advancements that are impacting the future of cancer care.
The panel discussion includes information on the newest diagnostic and treatment options available to patients, how changes in technology have impacted cancer care, forecasts for new technology advancements, and other topics driving innovation in the industry.
"The Future of Cancer Care" insert will be available in print editions of USA TODAY on September 20 in the following markets: New York City, Philadelphia, Washington D.C., Baltimore, Cincinnati and Chicago. USA TODAY online sites have 26.3 million unique visitors per month. An online version of the insert is available at:
A PDF of the insert as featured in USA TODAY is available at:
CGIX is a sponsor of "The Future of Cancer Care" insert.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations RedChip Companies, Inc. Jon Cunningham, 800-733-2447, ext. 107 email@example.comSource:Cancer Genetics